Skip to main content
. 2020 Sep 30;16(15):3028–3036. doi: 10.7150/ijbs.51234

Figure 5.

Figure 5

Prognosis of TMPRSS2 and IFITM3 in cancers. (A-C) The expression level and overall survival of TMPRSS2 in BRCA (A), LUAD (B) and UCEC (C) compared with normal samples. (D-E) The expression level and overall survival of IFITM3 in KIRC (D) and PRAD (E). (F) Prognosis analysis of TMPRSS2 and IFITM3 in different type of cancers by LOGpc system.